Edwards Lifesciences Corporation (EW)

In the past six months, Edwards Lifesciences' stock reached a 52-week high, experienced a downgrade by Oppenheimer and an upgrade by Evercore ISI, while Piper Sandler maintained an Overweight rating. Wells Fargo & Company raised its price objective, and BTIG Research upgraded Edwards Lifesciences. Morgan Stanley also increased its price target for the company. Edwards Lifesciences announced a $500 million accelerated share repurchase and reported strong third-quarter 2025 earnings. There has also been news of a Rosen Law Firm investigation. Positive clinical trial data for its SAPIEN M3 and EVOQUE systems, as well as long-term benefits of SAPIEN 3 TAVR, were presented at TCT 2025. The company also announced a new study exploring personalized blood pressure targets using its HemoSphere Advanced Monitoring Platform.

Information directly addressing the demand seasonality for Edwards Lifesciences' specific products and services is not explicitly available in the provided search results.

Edwards Lifesciences Corp. is an American medical technology company specializing in patient-focused medical innovations for heart disease and critical care monitoring. The company operates within the Health Technology sector and the Medical Specialties industry. Its major product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. Key products include the Sapien transcatheter aortic heart valve, SAPIEN M3, EVOQUE system, and the HemoSphere Advanced Monitoring Platform. Edwards Lifesciences is recognized as a global leader in structural heart innovation.

Edwards Lifesciences has a broad global presence, with its headquarters located in Irvine, California, U.S. The company operates through several geographical segments: the United States, Europe, Japan, and the Rest of World. Manufacturing facilities are situated in various locations worldwide, including Irvine, California; Draper, Utah; Costa Rica; the Dominican Republic; Puerto Rico; Singapore; and Limerick, Ireland.

Edwards Lifesciences has maintained a strong brand reputation over the past year, driven by its focus on innovative technologies, robust clinical evidence, and a patient-centered culture. The company's leadership in structural heart innovation is well-recognized. Positive outcomes from clinical trials have further bolstered its reputation. While a Rosen Law Firm investigation into potential breaches of fiduciary duties by leadership has been reported, its specific impact on the overall brand reputation in the past year is not explicitly detailed as significant in the provided information.

Major institutional investors hold a significant portion of Edwards Lifesciences' stock, with institutional ownership reported at 88.34% and 85.88%. Insider ownership stands at 0.91%.